Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management

International Journal of Clinical Practice

Volumn 64, Issue 3, 2010, Pages 295-304

  Prato, S Del ^a   Lasalle, J ^b   Matthaei, S ^c   Bailey, C J ^d  

^a UNIVERSITY OF PISA   (Italy)

^b Medical Arts Research Collaborative   (United States)

^c Diabetes Center   (Germany)

^d ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROPAMIDE; GLIBENCLAMIDE; INSULIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; CONTROL STRATEGY; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INDIVIDUALIZATION; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; WEIGHT GAIN;

ADULT; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; OBESITY; OVERWEIGHT; PRACTICE GUIDELINES AS TOPIC; THINNESS;

EID: 74349097849     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02227.x     Document Type: Conference Paper

References (28)

1. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 358 : 2545 2559.
2. Bailey CJ, Blonde L, Del Prato S et al. What are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes Management. Diab Vasc Dis Res 2009 6 : 283 287.
3. Advance Collaborative Group, Patel A, MacMahon S et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 58 : 2560 2572.
4. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009 360 : 129 139.
5. Ray KK, Seshasai SRK, Wijesuriya S et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009 373 : 1765 1772.
6. Mannucci E, Monami M, Lamanna C et al. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: A meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2009. [Epub ahead of print] doi: 10.1016/j.numecd.2009.03.021.
7. Del Prato S, Felton A-M, Munro N et al. Improving glucose management: ten steps to get more patients with type 2 diabetes to goal. Recommendations from the Global Partnership for Effective Diabetes Management. Int J Clin Pract 2005 59 : 1345 1355.
8. Bailey C, Del Prato S, Eddy D et al. Earlier intervention in type 2 diabetes: the case for achieving early and sustained glycaemic control. Int J Clin Pract 2005 59 : 1309 1316.
9. Goldstein BJ, Gomis R, Lee HK et al. Type 2 diabetes - treat early, treat intensively. Int J Clin Pract Suppl 2007 61 (Suppl. 157 16 21.
10. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 359 : 1577 1589.
11. Writing Team for the DCCT/EDIC Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. J Am Med Assoc 2002 287 : 2563 2569.
12. Writing Team for the DCCT/EDIC Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. J Am Med Assoc 2003 290 : 2159 2167.
13. Nathan DM, Lachin J, Cleary P et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003 348 : 2294 2303.
14. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. N Engl J Med 2005 353 : 2643 2653.
15. Ceriello A, Ihnat MA, Thorpe JE. Clinical review 2: the "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 2009 94 : 410 415.
16. Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008 93 : 1143 1152.
17. Del Prato S. Megatrials in type 2 diabetes. From excitement to frustration? Diabetologia 2009 52 : 1219 1226.
18. Duckworth W. Glycemic Control and Cardiovascular Outcomes - The VA Diabetes Trial. Oral presentation at the American Diabetes Association 68th Scientific Sessions. San Francisco, CA: American Diabetes Association, 2008. June 8.
19. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 853.
20. Brunetti P. The lean patient with type 2 diabetes: characteristics and therapy challenge. Int J Clin Pract 2007 61 : 3 9.
21. Sinharoy K, Mandal L, Chakrabarti S et al. A study on clinical and biochemical profile of low body weight type 2 diabetes mellitus. J Indian Med Assoc 2008 106 : 747 750.
22. Copeland KC, Chalmers LJ, Brown RD. Type 2 diabetes in children: oxymoron or medical metamorphosis? Pediatr Ann 2005 34 : 686 697.
23. International Diabetes Federation. Global Guidelines for Type 2 Diabetes. Brussels, Belgium : IDF, 2005.
24. Hsia Y, Neubert AC, Rani F et al. An increase in the prevalence of type 1 and 2 diabetes in children and adolescents: results from prescription data from a UK general practice database. Br J Clin Pharmacol 2009 67 : 242 249.
25. Aschner P, Lasalle J, McGill M et al. The team approach to diabetes management: partnering with patients. Int J Clin Pract 2007 61 (Suppl. 157 22 30.
26. Calles J, Banerji M, Bonds DE et al. Baseline characteristics and mortality in ACCORD. Diabetes 2009 58 (Suppl. 1 A24.
27. Skyler JS, Bergenstal R, Bonow RO et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009 32 : 187 192.
28. Kosiborod M, Inzucchi SE, Krumholz HM et al. Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation 2008 117 : 1018 1027.